Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment

E Grande, RD Harvey, B You, JF Batlle… - … of Pharmacology and …, 2019 - ASPET
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …
被引用次数：18 相关文章

Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment

E Grande, RD Harvey, B You, JF Batlle… - Journal of …, 2019 - scholars.uthscsa.edu
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …

Pharmacokinetic study of osimertinib in cancer patients with mild or moderate hepatic impairment

E Grande, RD Harvey, B You, JF Batlle… - … of Pharmacology and …, 2019 - ASPET
Osimertinib, an EGFR-tyrosine kinase inhibitor, undergoes significant hepatic elimination.
This phase 1 study (NCT02161770) assessed the effects of mild and moderate hepatic …

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

E Grande, RD Harvey, B You… - The Journal of …, 2019 - pubmed.ncbi.nlm.nih.gov
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

E Grande, RD Harvey, B You, JF Batlle… - The Journal of …, 2019 - europepmc.org
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …
[HTML] nih.gov

[HTML][HTML] Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment

E Grande, RD Harvey, B You, JF Batlle… - The Journal of …, 2019 - ncbi.nlm.nih.gov
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …

Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment.

E Grande, RD Harvey, B You, JF Batlle… - The Journal of …, 2019 - europepmc.org
Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI),
undergoes significant hepatic elimination. In this phase 1 study, we assessed the effects of …